What are PARP inhibitor drugs?

PARP inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting PARP1 and PARP2 enzymes). 3 are currently marketed, with 16 more in clinical development.

What are the marketed PARP inhibitor drugs?

Marketed PARP inhibitor drugs include Talzenna, Pharmacokinetics, Dosage of Niraparib, Olaparib Treatment D.

PARP inhibitor

3 marketed 10 in Phase 3 6 in Phase 2

This page covers all PARP inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PARP1 and PARP2 enzymes, PARP1, PARP2, PARP1/PARP2.

Targets

PARP1 and PARP2 enzymes · PARP1, PARP2 · PARP1/PARP2 · PARP · PARP (poly(ADP-ribose) polymerase) · PARP1 · PARP1 and PARP2

Marketed (3)

Talzenna · Pfizer Inc. · Oncology · 182
PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers.
Pharmacokinetics, Dosage of Niraparib · Hospices Civils de Lyon · Oncology
Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and leading to cell death.
Olaparib Treatment D · AstraZeneca · Oncology
Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death, particularly in BRCA-mutant tumors.

Phase 3 pipeline (10)

Fluzoparib Monotherapy · Tianjin Medical University Cancer Institute and Hospital · Oncology
Fluzoparib is a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes, preventing DNA repair and inducing cell death in cancer cells.
Pamiparib capsule · BeiGene · Oncology
Pamiparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair and causing cancer cell death.
ddAC-CP-Olaparib · The Netherlands Cancer Institute · Oncology
ddAC-CP-Olaparib is a PARP inhibitor that works by blocking the enzyme PARP, which is involved in DNA repair.
Iniparib (SAR240550/BSI-201) · Sanofi · Oncology
Iniparib inhibits poly(ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair, thereby sensitizing cancer cells to chemotherapy and radiation.
Saruparib (AZD5305) · AstraZeneca · Oncology
Saruparib is a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes to prevent DNA repair and induce cancer cell death.
Active Comparator: Olaparib tablets · AstraZeneca · Oncology
Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death, particularly in BRCA-mutant tumors.
Fluzoparib Capsules · The First Affiliated Hospital of Xiamen University · Oncology
Fluzoparib is a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes, preventing DNA repair in cancer cells and leading to cell death.
Olaparib tablet · Fondazione Ricerca Traslazionale · Oncology
Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death.
Active comparator: Niraparib · Tesaro, Inc. · Oncology
Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and leading to cell death.
Placebo to veliparib · AbbVie · Oncology
Veliparib is a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes, preventing DNA repair and causing cancer cell death.

Phase 2 pipeline (6)

CO-1.01 · Clovis Oncology, Inc. · Oncology
CO-1.01 is a poly(ADP-ribose) polymerase (PARP) inhibitor that blocks DNA repair mechanisms in cancer cells, leading to cell death.
Arm A - Olaparib · GERCOR - Multidisciplinary Oncology Cooperative Group · Oncology
Olaparib is a PARP inhibitor that blocks the enzyme PARP1, preventing cancer cells from repairing DNA damage.
ABT-888 · AbbVie (prior sponsor, Abbott) · Oncology
ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes.
BGB-290 · BeiGene · Oncology
PARP inhibitor
AZD2281 · AstraZeneca · Oncology
PARP inhibitor
AZD6738 and olaparib · AstraZeneca · Oncology
PARP inhibitor